140548例非转移性前列腺癌患者中靶向治疗相关转录组特征潜在候选者的患病率
结果显示低AR-A评分、基底亚型、PTEN缺失、HRD及高PSMA表达的比例随AJCC分期和Decipher风险升高而增加(均p<0.001),AJCC IIC-IIIC期且Decipher评分>0.85者中超过60%为靶向治疗潜在候选者。
要点
- 低AR-A评分和基底亚型比例随AJCC分期及Decipher风险升高而增加。
- PTEN缺失和HRD比例同样随分期和Decipher评分升高(均p<0.001)。
- AJCC IIC-IIIC期且Decipher评分>0.85者超60%为靶向治疗潜在候选者。
核心结论
- 治疗相关特征评分随AJCC分期和Decipher评分变化,可能有助于指导临床试验和靶向治疗选择。
主要发现
- 低AR-A评分和基底亚型比例随AJCC分期和Decipher基因组风险增加。
- PTEN缺失和HRD比例随AJCC分期和Decipher评分增加(均p<0.001)。
- 高PSMA表达在AJCC IIC-IIIC期疾病中更常见。
- AJCC IIC-IIIC期且Decipher评分>0.85者中超过60%为靶向治疗潜在候选者。
关键数值与推荐
- 低AR-A评分和基底亚型与ADT反应性较低相关。
- PTEN缺失提示对PI3K抑制剂潜在反应,HRD状态提示对PARP抑制剂潜在反应。
- 高PSMA表达提示为PSMA放射性配体治疗的潜在候选者。
临床怎么用
- 治疗相关特征评分可用于指导非转移性前列腺癌的临床试验设计和靶向治疗选择。
- 更高分期前列腺癌更倾向基底型和雄激素非依赖,可能对强化ADT+AR通路抑制剂或靶向PARP/PSMA的治疗更敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Systemic therapies that have shown a benefit in advanced prostate cancer are being evaluated in earlier disease stages. We sought to determine the prevalence of transcriptomic changes in signatures related to treatment susceptibilities in patients with nonmetastatic prostate cancer. METHODS: Patients with nonmetastatic prostate cancer with Decipher genomic classifier and whole-transcriptome profiling data for biopsy specimens from October 2016 to February 2024 were included (n = 140 548). Predefined treatment-related signatures of androgen receptor activity (AR-A), PTEN loss, homologous recombination deficiency (HRD), RB loss, immune activity, and prostate-specific membrane antigen (PSMA; FOLH1) expression, along with Decipher scores and prostate cancer subtypes, were assessed. KEY FINDINGS AND LIMITATIONS: The prevalence of low AR-A scores and the basal subtype, which are associated with lower responsiveness to androgen deprivation therapy (ADT), increased with American Joint Committee on Cancer (AJCC) stage and Decipher genomic risk. The prevalence of cancers with a potential response to PI3K inhibitors, according to PTEN loss, and a response to PARP inhibitors, according to HRD status, also increased with AJCC stage and Decipher genomic risk score (all p < 0.001). The prevalence of high PSMA expression was greater in AJCC grade IIC-IIIC disease, so these patients would be potential candidates for PSMA radioligand therapies. More than 60% of patients with AJCC grade IIC-IIIC disease and very high Decipher scores (>0.85) are potential candidates for targeted therapies. CONCLUSIONS AND CLINICAL IMPLICATIONS: Treatment-related signature scores vary by AJCC stage and Decipher score and may be useful in guiding trials and selecting targeted therapies for nonmetastatic prostate cancer. Higher-stage prostate cancers appear to be more basal and androgen-independent, and thus may be more susceptible to intensified ADT + androgen receptor pathway inhibitors or therapies targeting PARP or PSMA.
引用
- Handa N, Li EV, Michael J, et al. Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate Cancer. Eur Urol Oncol. 2025. PMID: 40350343. doi:10.1016/j.euo.2025.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。